 Shares of Repare Therapeutics Inc. RPTX, -4.68 jumped 24.5 in premarket trading on Thursday, the day after the company said it signed a worldwide licensing and collaboration agreement with Roche Holding AG ROG, 0.74 to develop and commercialize Repares experimental tumor treatment. The drug, camonsertib, is being tested as a way to treat tumors with specific synthetic-lethal genomic alterations. 